
    
      The study was conducted as an open label, randomized, single-center, single-dose,
      two-treatment, two-period, crossover bioavailability of the test formulation of cetirizine
      hydrochloride tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) containing
      containing 10 mg cetirizine hydrochloride study comparing to the marketed product, ZyrtecÂ®,
      containing 10 mg of cetirizine hydrochloride of Pfizer Labs (Division of Pfizer Inc.), in
      healthy, adult, human, subjects under fasting condition.

      Safety measures were performed throughout the study and included a physical examination,
      laboratory evaluation, and measurement of vital signs.

      A total of 32 subjects were randomized to receive single oral dose of cetirizine
      hydrochloride 10 mg tablet and 31 subjects completed both the periods of the study.
    
  